An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

Child and Adolescent Psychiatry and Mental Health

Volumn 6, Issue , 2012, Pages

  Pandina, Gahan ^a   Kushner, Stuart ^a   Karcher, Keith ^a   Haas, Magali ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Adolescent schizophrenia; Long term treatment; Risperidone

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE;

ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; AGITATION; AMENORRHEA; ANXIETY; ARTICLE; AUTOMUTILATION; BODY MASS; BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DELUSION; DEPRESSION; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INJURY; INSOMNIA; LACTATION; LIBIDO; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MENTAL DISEASE; MENTAL INSTABILITY; MULTICENTER STUDY; MUSCLE HYPERTONIA; OPEN STUDY; OUTCOME ASSESSMENT; PARANOIA; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; RHINITIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; VITAL SIGN; VOMITING;

EID: 84861898743     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-6-23     Document Type: Article

References (40)

1. Asarnow JR, Tompson MC, Goldstein MJ. Childhood-onset schizophrenia: a followup study. Schizophr Bull 1994, 20:599-617.
2. Remschmidt H, Theisen FM. Schizophrenia and related disorders in children and adolescents. J Neural Transm Suppl 2005, 121-141.
3. Remschmidt HE, Schulz E, Martin M, Warnke A, Trott GE. Childhood-onset schizophrenia: history of the concept and recent studies. Schizophr Bull 1994, 20:727-745.
4. Schimmelmann BG, Conus P, Cotton S, McGorry PD, Lambert M. Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res 2007, 95:1-8. 10.1016/j.schres.2007.06.004, 17628441.
5. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008, 165:1432-1441. 10.1176/appi.ajp.2008.07061035, 18765484.
6. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008, 34:60-71. 2632383, 17923452.
7. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008, 165:1420-1431. 10.1176/appi.ajp.2008.08050756, 18794207.
8. Haas M, Eerdekens M, Kushner S, Singer J, Augustyns I, Quiroz J, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009, 194:158-164. 10.1192/bjp.bp.107.046177, 19182179.
9. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009, 19:611-621. 10.1089/cap.2008.0144, 20035579.
10. Tohen M, Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007, 164:1547-1556. 10.1176/appi.ajp.2007.06111932, 17898346.
11. Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry 2009, 70:247-258. 10.4088/JCP.08m03538, 19210948.
12. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006, 45:771-791. 10.1097/01.chi.0000220851.94392.30, 16832314.
13. Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry 2008, 20:195-201. 10.1080/09540260801889179, 18386212.
14. Correll CU. Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia. J. Clin Psych 2011, 72(1):e01.
15. Haas M, Karcher K, Pandina GJ. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. J Child Adolesc Psychopharmacol 2008, 18:337-345. 10.1089/cap.2007.0098, 18759643.
16. Pandina GJ, Aman MG, Findling RL. Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol 2006, 16:379-392. 10.1089/cap.2006.16.379, 16958564.
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
18. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997, 58:538-546. 10.4088/JCP.v58n1205, 9448657.
19. Guy W(. ECDEU Assessment Manual for Psychopharmacology 1976, 218-222.
20. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983, 40:1228-1231. 10.1001/archpsyc.1983.01790100074010, 6639293.
21. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969, 44:291-303. 10.1136/adc.44.235.291, 2020314, 5785179.
22. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970, 45:13-23. 10.1136/adc.45.239.13, 2020414, 5440182.
23. Abnormal involuntary movement scale. ECDEU Assessment Manual for Psychopharmacology 1976, 534-537. Rockville, MD: US Department of Health, Education, and Welfare, Guy W.
24. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
25. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676. 10.1192/bjp.154.5.672, 2574607.
26. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Shetty TK, Gangadhar BN. A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia. Clin Neuropharmacol 2010, 33:288-292. 10.1097/WNF.0b013e3181fa2a6f, 21060283.
27. Kim BJ, Sohn JW, Park CS, Hahn GH, Koo J, Noh YD, et al. Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. J Korean Med Sci 2008, 23:685-690. 10.3346/jkms.2008.23.4.685, 2526396, 18756058.
28. Monteleone P, Fabrazzo M, Tortorella A, La Pia S, Maj M. Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. J Clin Psychopharmacol 2002, 22:424-426. 10.1097/00004714-200208000-00015, 12172344.
29. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res 2003, 60:99-100.
30. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992, 28:213-218.
31. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992, 85:295-305. 10.1111/j.1600-0447.1992.tb01473.x, 1375801.
32. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994, 151:825-835.
33. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993, 13:25-40.
34. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995, 166:712-726. 10.1192/bjp.166.6.712, 7545060.
35. Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002, 110:e34. 10.1542/peds.110.3.e34, 12205284.
36. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 2004, 161:677-684. 10.1176/appi.ajp.161.4.677, 15056514.
37. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006, 163:402-410. 10.1176/appi.ajp.163.3.402, 16513860.
38. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 2006, 16:260-272. 10.1089/cap.2006.16.260, 16768634.
39. Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Eur Child Adolesc Psychiatry 2006, 15:97-104. 10.1007/s00787-006-0504-0, 16523250.
40. American Academy of Child and Adolescent Psychiatry Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2001, 40:4S-23S. 10.1097/00004583-200107001-00002, 11434484, American Academy of Child and Adolescent Psychiatry.